Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms...
Childhood Hepatocellular CarcinomaPapillary Thyroid Cancer5 moreThis phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer. Sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
Adult Malignant MesenchymomaAdult Rhabdomyosarcoma9 moreThis randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Adult RhabdomyosarcomaAdult Synovial Sarcoma11 moreThis phase II trial is studying how well ixabepilone works in treating young patients with refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Childhood Chronic Myelogenous LeukemiaChildhood Desmoplastic Small Round Cell Tumor12 moreThis phase I trial is studying the side effects and best dose of tanespimycin in treating young patients with recurrent or refractory leukemia or selected solid tumors. Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die.
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients...
Adult RhabdomyosarcomaEmbryonal Childhood Rhabdomyosarcoma2 moreThis phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective in treating low-risk rhabdomyosarcoma.
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
HepatoblastomaPreviously Treated Childhood Rhabdomyosarcoma9 moreThis phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma...
Adult RhabdomyosarcomaChildhood Alveolar Rhabdomyosarcoma4 moreThis randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving temozolomide and cixutumumab together with combination chemotherapy may kill more tumor cells.
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced,...
Adult AngiosarcomaAdult Desmoplastic Small Round Cell Tumor33 moreThis phase I trial is studying the side effects and best dose of cixutumumab given together with doxorubicin hydrochloride and to see how well they work in treating patients with unresectable, locally advanced, or metastatic soft tissue sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody cixutumumab together with doxorubicin hydrochloride may kill more tumor cells.
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Adult RhabdomyosarcomaLung Metastases13 moreThis pilot clinical trial studies intensity-modulated radiation therapy (IMRT) in treating younger patients with lung metastases. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor...
Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous Leukemia23 moreThis phase II trial is studying how well etanercept works in treating young patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant. Etanercept may be effective in treating patients with idiopathic pneumonia syndrome after undergoing a donor stem cell transplant.